SCHEMBL15613596

SCHEMBL15613596

Nc1ncnc2c1c(-c1ccc(Br)cc1)nn2CCN1CCOCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 10/20 0.65
▸ YES1 P07947 6/20 0.65
▸ FGR P09769 6/20 0.65
▸ FYN P06241 6/20 0.60
▸ LYN P07948 4/20 0.60
▸ ABL1 P00519 5/20 0.58
▸ FRK P42685 4/20 0.58
▸ LCK P06239 3/20 0.58
▸ RET P07949 3/20 0.58
▸ FGFR2 P21802 5/20 0.48
▸ FGFR1 P11362 5/20 0.48
▸ FGFR4 P22455 4/20 0.48
▸ FGFR3 P22607 4/20 0.48
▸ BLK P51451 3/20 0.48
▸ HCK P08631 2/20 0.48
▸ PTK6 Q13882 2/20 0.48
▸ CYP1A2 P05177 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7902941 0.81 SRC (0.56) SRCYES1FGRFYNLYN
SCHEMBL20132621 0.79 SRC (1.00) SRCYES1FGRFYNLYN
SCHEMBL16127376 0.77 SRC (0.53) SRCYES1FGRFYNLYN
SCHEMBL20533043 0.75 CYP1A2 (0.61) SRCYES1FGRFYNLYN
SCHEMBL18250084 0.75 SRC (1.00) SRCYES1FGRFYNLYN
SCHEMBL15613506 0.75 PIK3CD (0.59) SRCLYNABL1LCKRET
SCHEMBL16886112 0.74 PIK3CD (0.68) SRCYES1FGRFYNLYN
SCHEMBL2965908 0.74 IGF1R (0.71) —
SCHEMBL20132576 0.74 SRC (1.00) SRCYES1FGRFYNLYN
SCHEMBL15613692 0.73 BTK (0.47) SRCYES1FGRFYNLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK SRC 2/4885YES1 39/4885FGR 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback